ASH 2020 | Single versus double induction with 7+3 for newly diagnosed AML

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, outlines the results of the randomized-controlled SAL-DaunoDouble trial (NCT02140242), comparing remission and survival in newly diagnosed acute myeloid leukemia (AML) patients treated after single versus double induction with 7+3 regimens of cytarabine plus daunorubicin. Given the lack of evidence for the necessity of a second cycle in patients with a rapid response to the first, nearly 300 patients who had achieved a marrow blast clearance below 5% by day 15 of the first induction cycle were randomized to receive no second induction cycle or second induction cycle. Interim analysis results demonstrated that the difference between complete response rates for single versus double induction was lower than the predefined 7.5% margin, indicating non-inferiority of single induction in good responders. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.